| Document |
Document Title |
|
WO/2013/062680 |
The present invention relates to a novel compound, methods of synthesizing the compound, compositions containing the compound, and methods for using the compound or composition to treat and/or prevent diseases and/or conditions of the ce...
|
|
WO/2013/062074 |
A novel imidazolone derivative represented by general formula (I) and having the action of a positive allosteric modulator with respect to the metabotropic glutamate receptor subtype 2 (mGlu2 receptor), or a pharmaceutically acceptable s...
|
|
WO/2013/062079 |
The present invention relates to: a dihydroimidazooxazole derivative represented by general formula (IA) or a pharmaceutically acceptable salt thereof, which has positive allosteric modulator activity on metabotropic glutamate receptor s...
|
|
WO/2013/060636 |
The present invention relates to 1 H-pyrazolo[3,4-b]pyridine compounds of the formula (I) in which R1, R2, R3 and R4 are defined as indicated below. The compounds of the formula I are protein kinase C (PKC) inhibitors, and are useful for...
|
|
WO/2013/060668 |
It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevent...
|
|
WO/2013/063309 |
The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allow...
|
|
WO/2013/062444 |
The invention relates to the biologically active peptides which block nicotinic acetylcholine receptors and can find application in the field of biochemistry, biotechnology and medicine. Peptide azemiopsin has the following amino acid...
|
|
WO/2013/062027 |
The invention according to the present application provides a therapeutic or prophylactic agent for diseases including mood disorders, anxiety disorders, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eatin...
|
|
WO/2013/061279 |
The present invention provides a method of using indole-ketone or mdolidone to treat or prevent a neurodegenerative disease or disorder. In one embodiment, the neurodegenerative disease is Parkinson's disease. In another embodiment, the ...
|
|
WO/2013/061106 |
The invention relates to toxin peptides capable of selectively inhibiting a Kv1.3 potassium channel protein. The toxin peptides of the invention are modified anuroctonus scorpion toxin peptides.˙
|
|
WO/2013/060097 |
The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereof, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment ...
|
|
WO/2013/060258 |
The present invention relates to 3 alkaloids (clavatine A-C) isolated from Lycopodium japonicum Thunb., a pharmaccodynamically acceptable salt thereof and a preparation method thereof, a pharmaceutical composition containing this class o...
|
|
WO/2013/061977 |
The present invention pertains to the compound represented by formula (I) (in the formula: X1, X2, X3, X4, X5, R5, R6, R7, R8, n, p, q, ring A, and ring B have the same meaning as the definitions described in the description) or a pharma...
|
|
WO/2013/060715 |
The present invention relates to the prophylactic and therapeutic use of extracts from the filipendula species for treating extrapyramidal motor disorders.
|
|
WO/2013/063086 |
This invention relates to antibody drug conjugates and methods of use thereof. More particularly, antibody drug conjugates comprising a cytoprotective agent are provided, wherein the conjugates are useful for the treatment of proteinopat...
|
|
WO/2013/063120 |
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, parti...
|
|
WO/2013/060029 |
Formula (I), and salts thereof, wherein R1, RA2, RA3 and RA4, are defined herein, which have properties for positive allosteric modulation of mGluR-4 receptor sites. Also described are pharmaceutical formulations comprising the compounds...
|
|
WO/2013/057944 |
The present invention provides a novel compound represented by general formula (1), which has an activity of activating glucokinase occurring in the liver and a pancreatic β cell and is useful as a prophylactic and/or therapeutic agent ...
|
|
WO/2013/059119 |
Glucosylceramide synthase inhibitore and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...
|
|
WO/2013/058258 |
[Problem] To provide a compound useful as the active ingredient in a drug composition for treating diseases to which 11β-hydroxysteroid dehydrogenase type 1 contributes such as dementia, schizophrenia, depression, pain (particularly neu...
|
|
WO/2013/059449 |
The present invention relates to the treatment of withdrawal and craving symptoms as an aid in smoking cessation by administration of one or more dosages of a medication containing Passiflora incarnata.
|
|
WO/2013/059222 |
The present invention is directed to 2-pyridyloxy-4-nitrile compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyl-oxy-4-nitrile compounds described herein in the treatment or...
|
|
WO/2013/057222 |
The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of ...
|
|
WO/2013/059791 |
Provided are methods for promoting axon regeneration of a Central Nervous System (CNS) neuron and promoting nerve function following injury to a CNS neuron, for example, brain and/or spinal cord injury. Axon regeneration in a CNS neuron ...
|
|
WO/2013/058303 |
The present invention provides a medicinal composition capable of preventing a decrease in the blood exposure level of a third generation coxib drug, a method for preparing the composition and utilization of the same. It was discovered t...
|
|
WO/2013/059786 |
Synthetic methylated peptides derived from the tau protein of paired helical filaments and non-diseased control brain are disclosed. Alzheimer's disease specificity is provided by the presence or absence of methyl moieties on lysine resi...
|
|
WO/2013/058605 |
The present invention relates to a pharmaceutical composition comprising fluoxetine as an active ingredient for preventing or treating blood-brain barrier disorders. More particularly, it is defined that fluoxetine may inhibit expression...
|
|
WO/2013/056326 |
The present invention relates to a pharmaceutical composition for the treatment of diseases related to a drug addiction containing from 250 to 500 mg of naltrexone, preferably 300 to 400 mg of naltrexone, and most preferably 380 mg of na...
|
|
WO/2013/058681 |
The invention relates to novel compounds of general formula 1, namely substituted phenoxyacetic acids and esters and amides thereof, which comprise a 2,6-dioxo-2,3,6,7-tetrahydro-1H-purine-8-yl fragment and exhibit antagonist activity ag...
|
|
WO/2013/057554 |
Combinations of netupitant and palonosetron, and methods of using such combinations to treat various pain states and irritable bowel syndrome, are provided.
|
|
WO/2013/057322 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a...
|
|
WO/2013/057124 |
The instant invention relates to novel solid forms of the compound of formula (I), as well as solvates, inclusion complexes with other suitable compounds, processes for their manufacture, pharmaceutical compositions containing these soli...
|
|
WO/2013/054267 |
Pharmaceutical or dietary supplement composition, comprising, as active ingredients with combined or synergistic effect, curcumin and astaxanthin, for use in the prevention and treatment of disorders connected with ageing of the organism.
|
|
WO/2013/054534 |
The present invention relates to the provision of drugs for the treatment or prevention of conditions, disorders, or diseases associated with amyloid β. Provided is a method of screening for drugs for the treatment or prevention of dise...
|
|
WO/2013/053485 |
The invention relates to a quetiapine granulate consisting of quetiapine or a salt thereof, a copolymer of methacrylic acid esters, and a sugar alcohol, wherein the mass ratio between quetiapine or a salt thereof and the copolymer of met...
|
|
WO/2013/055865 |
The invention provides methods for diagnosing neurodegenerative disorders (e.g., amyotrophic lateral sclerosis and multiple sclerosis) in a subject, identifying subjects at risk of developing a neurodegenerative disorder, predicting the ...
|
|
WO/2013/056181 |
Provided herein are 3,3-disubstituted 19-nor- steroidal compounds according to Formula (I) and (III): where R1,R2, R3, R3', R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful fo...
|
|
WO/2013/054582 |
The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising ...
|
|
WO/2013/055687 |
The subject invention provides R (+) -N-formyl-propargyl- aminoindan and a composition containing N-propargyl-1 (R) -aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R (+) -N-formyl-propargyl-aminoindan.
|
|
WO/2013/056232 |
|
|
WO/2013/053287 |
(-)-(S)-3-(3'-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-impro...
|
|
WO/2013/056105 |
|
|
WO/2013/055386 |
Methods for treating Down syndrome and improving cognitive function of a patient with an intellectual disability are disclosed. 5-hydroxytryptophan sub-receptor six (5-HT6) receptor antagonists are provided for improving the cognition of...
|
|
WO/2013/055833 |
S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
|
|
WO/2013/054940 |
The purpose of the present invention is to provide a novel therapeutic agent and preventive agent for demyelinating disease. The present invention is a therapeutic agent and a preventive agent for demyelinating disease that contain as an...
|
|
WO/2013/055922 |
Provided herein are methods for decreasing blood-brain barrier permeability in a subject with neuroinflammatory disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically bind...
|
|
WO/2013/053690 |
This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable...
|
|
WO/2013/055385 |
The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enha...
|
|
WO/2013/053725 |
The present invention relates to 2-oxo-piperidinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
|
|
WO/2013/054866 |
The present invention provides an agent for preventing or treating HAM and containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as the active ingredient. The present invention also provides an agent for ameliorat...
|
